New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni Abstract: Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between [...]

October 5th, 2021|Publications|

FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

Frederik L Giesel 1, Sebastian Adeberg 2 3 4 5, Mustafa Syed 2 4, Thomas Lindner 1, Luis David Jiménez-Franco 6, Eleni Mavriopoulou 1, Fabian Staudinger 1, Eric Tonndorf-Martini 2 4, Sebastian Regnery 2 4, Stefan Rieken 2 5 7, Rami El Shafie 2 5, Manuel Röhrich 1, Paul Flechsig 1, Andreas Kluge 6, Annette Altmann 1, Jürgen Debus 2 3 4 5, Uwe Haberkorn 8 9, Clemens Kratochwil 1 Abstract: 68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life [...]

February 24th, 2021|Publications|

68 Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [ 18 F] FDG PET/CT

Guochang Wang # 1, Xiao Jin # 1, Hua Zhu 1, Shuailiang Wang 1, Jin Ding 1, Yan Zhang 1, Zhi Yang 2, Xuejuan Wang 3 Article available for purchase or with subscription. Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China. [...]

February 24th, 2021|Publications|

Fibroblast Activation Protein-Targeted PET/CT with 68 Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18 F-FDG PET/CT

Yaping Luo 1 2, Qingqing Pan 1 2, Huaxia Yang 3, Linyi Peng 3, Wen Zhang 3, Fang Li 4 2 Abstract: IgG4-related disease (RD) is characterized by lymphoplasmacytic infiltration enriched in IgG4-positive plasma cells and variable degrees of fibrosis with a characteristic storiform pattern. Since fibrosis is an important feature of IgG4-RD, we performed a prospective cohort [...]

February 6th, 2021|Publications|

[ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions

Bing Hao 1, Xiurong Wu 2, Yizhen Pang 1, Long Sun 1, Hua Wu 1, Weipeng Huang # 3, Haojun Chen # 4 Article available for purchase or with subscription. Affiliations: Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Department of [...]

February 2nd, 2021|Publications|

Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer

Artineh Hayrapetian 1, Mark D Girgis, Jane Yanagawa, Samuel W French, Heinrich R Schelbert 1, Martin S Auerbach 1, Johannes Czernin, Jeremie Calais Abstract: A 71-year-old man underwent 18F-FDG and 68Ga-FAPI-46 PET/CT for initial staging prior to surgery of a squamous cell carcinoma of the lower esophagus under the prospective study NCT04147494. Both scans showed [...]

February 1st, 2021|Publications|

Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18 F-Labeled FAP Inhibitor

Johannes Toms 1, Jürgen Kogler 1, Simone Maschauer 1, Christoph Daniel 2, Christian Schmidkonz 3, Torsten Kuwert 3, Olaf Prante 4 3 Fibroblast activation protein (FAP) has emerged as an interesting molecular target used in the imaging and therapy of various types of cancers. 68Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been successfully applied to PET imaging of various tumor [...]

December 6th, 2020|Publications|

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

Christian Schmidkonz 1, Simon Rauber 2, Armin Atzinger 1, Rahul Agarwal 2, Theresa Ida Götz 1, Alina Soare 2, Michael Cordes 1, Olaf Prante 1, Christina Bergmann 2, Arnd Kleyer 2, Philipp Ritt 1, Simone Maschauer 1, Peter Hennig 1, Johannes Toms 1, Markus Köhner 1, Bernhard Manger 2, John H Stone 3, Uwe Haberkorn 4, Tobias Baeuerle 5, Jörg H W Distler 2, Abbas Agaimy 6, Torsten Kuwert 1, Georg Schett 2, Andreas Ramming 7 Objectives: To date, there is no valuable tool to assess fibrotic disease activity in humans in [...]

November 5th, 2020|Publications|

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers?

Patrick Conen 1 2, Felix M Mottaghy 3 4 5 Purpose: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) have been associated with the aggressive nature of head and neck cancers (HNCs). These tumours grow diffusely, leading to extremely challenging differentiation between tumour and healthy tissue. This analysis aims to introduce [...]

November 4th, 2020|Publications|

68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient

Liang Zhao 1, Jianwei Gu 2, Kaili Fu 1, Qin Lin 1, Haojun Chen 2 Abstract: Ga-FAPI PET/CT was performed in a 56-year-old cirrhotic patient with multiple liver nodules, which were suspected of hepatocellular carcinoma by contrast-enhanced magnetic resonance but were not visualized by F-FDG PET/CT. Increased Ga-FAPI liver uptake was observed in [...]

October 3rd, 2020|Publications|


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top